Sign in

Gerardo Hernandez

Chief Financial Officer and Treasurer at TransMedics Group
Executive

About Gerardo Hernandez

Gerardo Hernandez, age 54, has served as TransMedics’ Chief Financial Officer and Treasurer since December 2, 2024. He previously led Corporate FP&A at Alnylam (2020–2024), led FP&A integration at Takeda (2019–2020) following Shire’s acquisition, and headed Corporate FP&A at Shire (2010–2019); earlier he held finance roles at Unilever (1994–2010). He holds a B.S. in Finance (University of Wisconsin–La Crosse) and an MBA in Strategy & Economics (Fundação Getulio Vargas, São Paulo) . In 2024, TransMedics delivered 83% revenue growth to $441.5M, achieved operating profit of $37.5M and net income of $35.5M, and generated $48.8M of operating cash flow, with cumulative TSR of 328% since 2019 baseline, underscoring strong alignment between pay and performance during the period surrounding Hernandez’s appointment .

Past Roles

OrganizationRoleYearsStrategic Impact
Alnylam PharmaceuticalsVP Finance, Head of Corporate FP&A2020–2024Led global performance analysis and planning as company scaled from clinical-stage to global commercial enterprise .
Takeda PharmaceuticalsHead of Corporate FP&A Integration2019–2020Led FP&A through integration following Takeda’s $62B acquisition of Shire, supporting complex global integration .
Shire plcHead of Corporate FP&A (various finance roles)2010–2019Built and led corporate FP&A; instrumental in enterprise planning pre-acquisition .
Unilever plcFinance roles of increasing responsibility1994–2010Broad finance foundations across CPG; progressed through multiple roles .

Fixed Compensation

Component20242025
Annual base salary rate ($)$450,000 (established upon hire, annualized) $450,000
Salary paid in year ($)$17,308 (partial year from Dec 2, 2024) n/a (not disclosed)
Target annual bonus (%)Not eligible for 2024 bonus 50% of base salary
Actual annual bonus paid ($)Not applicable for 2024 Not disclosed

Performance Compensation

Equity Awards (Inducement grants at hire)

Award TypeGrant DateUnits/OptionsGrant-Date Fair Value ($)Vesting ScheduleExercise Price / Expiration
RSUs12/9/202412,463 870,416 25% annually on each of the first four anniversaries of 12/2/2024, subject to continued service n/a
Stock Options12/9/202418,922 869,748 25% on 12/2/2025; remaining 75% vests in equal monthly installments over 36 months thereafter, subject to service $69.84 strike; expires 12/9/2034
  • As of 12/31/2024, closing price was $62.35, so options were out-of-the-money ($62.35 < $69.84) .

Annual Bonus Program Structure (Company-wide; Hernandez not eligible in 2024)

MetricTargetActualResult/Payout Basis
Revenue$370M $441.5M Above “maximum” threshold ($435M); drives 200% payout for eligible NEOs
Impact Factor One goals (4)≥3 met to activate threshold 3 of 4 met Supports maximum payout when combined with revenue
Impact Factor Two goals (4)Considered qualitatively 3 of 4 met Considered in committee review (no additional discretion applied)

Equity Ownership & Alignment

ItemAmount / DetailAs ofNotes
Beneficial ownership (shares)331 3/31/2025Consists solely of shares underlying options exercisable within 60 days .
Shares outstanding (reference)33,827,880 3/31/2025Basis for % ownership computation .
Ownership as % of shares outstanding~0.001% (331 / 33,827,880) 3/31/2025Calculated from disclosed values .
Unvested RSUs (count; value)12,463 units; $777,068 market value (at $62.35) 12/31/202425% vests annually over 4 years .
Options (exercisable vs unexercisable)Exercisable: 0 as of 12/31/2024; Unexercisable: 18,922 12/31/202425% vests on 12/2/2025; monthly thereafter .
Stock ownership guidelines2x base salary; unvested time-based RSUs count; 5-year compliance window; C-level execs “on track” Adopted 1/1/2023Supports alignment; options and performance awards don’t count .
Hedging/PledgingAnti-hedging policy in place; no pledging disclosure in proxy Policy disclosed 2024/2025Insider trading policy prohibits hedging; pledging not specifically referenced .

Note: 2024 Option Exercises and Stock Vested table shows no exercises or vesting for Hernandez in 2024 (no entries), consistent with his December start date .

Employment Terms

ProvisionStandard Termination (after 12 months; no change-in-control)Termination within 24 months of Change-in-Control (double-trigger)Notes
Severance cashSum of highest base salary in prior 3 years + highest bonus in prior 3 years, payable over 12 months (reduced by any noncompete payments) Lump sum of 1.5× highest base salary (prior 3 years) + highest bonus (prior 3 years) + target current-year bonus Not eligible for pre-CIC severance until after first anniversary of start date .
Benefits continuationUp to 12 months Up to 18 months Group health insurance .
Equity vestingNo acceleration Full acceleration of unvested options and RSUs; performance-based awards vest at target Double-trigger acceleration .
Pro-rated annual bonusPro-rated based on prior year bonus Pro-rated based on prior year bonus Subject to release/compliance .
Noncompete / Non-solicit1-year post-termination noncompete and non-solicit (restrictive covenants) 1-year post-termination noncompete and non-solicit Per restrictive covenant agreements .
ClawbackCompany-wide Dodd-Frank/Nasdaq-compliant clawback policy on incentive-based pay (3-year lookback for restatements) Same Applies to Section 16 officers .
280G treatment“Better-of” provision; no excise tax gross-ups (shareholder-friendly) SameNo gross-ups; reduce or pay whichever yields higher after-tax .
IndemnificationStandard officer indemnification agreement StandardConsistent with company practice .

Estimated severance (disclosed scenarios, values as of 12/31/2024):

  • Change-in-control termination: Benefits $39,338; Severance $675,000; Equity acceleration $777,068; Total $1,491,406 .

Performance Compensation – Detailed Mechanics

MetricWeightingTargetActualPayoutVesting/Timing
RevenueFormulaic (cap 200%) $370M $441.5M Max 200% for eligible NEOs Annual bonus for 2024; Hernandez not eligible .
Strategic “Impact Factor One” (4 goals)Threshold gate ≥3 goals met 3/4 met Supports max payout 2024 program .
Strategic “Impact Factor Two” (4 goals)Qualitative modifier n/a3/4 met Considered; no extra discretion used 2024 program .

Investment Implications

  • Strong retention and alignment: Hernandez’s package skews to time-based RSUs and stock options with double-trigger acceleration under CIC and robust stock ownership guidelines (2× salary; RSUs count), anti-hedging policy, and clawback—favorable governance signals without excise tax gross-ups .
  • Limited near-term selling pressure: No 2024 vesting/exercises; first option tranche vests 12/2/2025; RSUs vest 25% annually thereafter; options were out-of-the-money at 12/31/2024 ($62.35 vs $69.84), reducing immediate sell pressure risk, though RSU settlements beginning 2025 may create periodic liquidity events .
  • Pay-for-performance context: Company’s bonus framework is revenue-driven with strategic gates; while Hernandez was not eligible in 2024, his 2025 target bonus is 50% of salary, indicating measured variable pay tied to the Company’s growth objectives and TSR track record .
  • Retention risk mitigants: One-year noncompete/non-solicit, severance economics after 12 months, and double-trigger CIC acceleration support continuity and incentivize value-preserving outcomes in strategic events .

Additional disclosures: No related party transactions involving Hernandez are reported; the 8-K states no material direct/indirect interest in related party transactions and no family relationships . The proxy does not disclose pledging by Hernandez; anti-hedging policy is in place .